In patients suffering from chronic heart failure, the heart cannot adequately pump blood to meet the body’s demands. As heart failure worsens, increased pressures can develop in the heart and pulmonary arteries, which previous research has shown to adversely affect patients’ health and increase the risk of hospitalization.
A new analysis of data from the CHAMPION study found that actively monitoring patients with the CardioMEMS HF System was more effective in reducing heart failure hospitalizations than conventional medical management.
The CardioMEMS HF System is the first and only FDA-approved heart failure monitor that, when used by physicians, has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in New York Heart Association (NYHA) Class III patients. Long-term, prospective data published in The Lancet supports the effectiveness of the CardioMEMS HF System at reducing heart failure hospitalizations by demonstrating the system can provide physicians the opportunity to proactively manage their heart failure patients.
The CHAMPION trial originally demonstrated a statistically and clinically significant 28 percent reduction in the rate of HF hospitalizations at six months, and a 37 percent reduction in HF hospitalizations during an average follow-up duration of 15 months.
More information could be found from St. Jude Website by clicking this link.
No comments:
Post a Comment